Harnessing the immune system to beat cancer
why
High unmet medical need
Many cancer patients do not benefit from current immunotherapies, such as immune checkpoint inhibitors*.
Up to 80% of the patients do not benefit from immuno checkpoint inhibitors*
*Chen, S. et al. "Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials." Front. Oncol. 11:562315 (2021).
How
Our technology
Ayuvant is developing a novel immunotherapy based on RNA-nanoparticles that instruct the immune system on how to recognise and attack cancer cells.
Our science
Unique features
Non-inflammatory RNA nanoparticle platform targeting the immune system
Specific immunotherapy inducing long-term memory effects
Strong antitumor activity in immune checkpoint inhibitors-resistant models
Team
Who we are
.JPG)
Our Partners and Supporters
News
Stay updated
July 10, 2023
From PhD research to cancer treatment: Lucas Czentner does it all
By starting a company, PhD candidate Lucas Czentner makes great strides
December 15, 2023
Exciting News! The Academic Startup Competition proudly unveils the top 20 finalists!
These visionary companies are set to make a significant impact across
